By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Corporation of North America 

500 Frank West Burr Boulevard
Suite 46
Teaneck  New Jersey  07666  U.S.A.
Phone: 201-692-8128 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Eisai Inc. (ESALF.PK) to Present New Research on Product Portfolio and Pipeline at American Society of Clinical Oncology Annual Meeting 5/19/2011 9:51:22 AM
Eisai Corporation of North America Release: FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS) 7/8/2009 8:07:04 AM
Eisai Corporation of North America and Pfizer Inc. (PFE) Decide not to Appeal NICE Decision and Call for an Expedited Review of Guidance for Alzheimer's Disease 7/1/2009 7:08:09 AM
Morphotek Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer 3/23/2009 7:29:44 AM
FDA Approves Eisai Corporation of North America's LUSEDRA(TM) Injection for Monitored Anesthesia Care (MAC) Sedation 12/15/2008 6:30:59 AM
FDA Approves Eisai Corporation of North America's BANZEL(TM) (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder 11/17/2008 6:58:56 AM
Morphotek Inc. Expands Its Phase II Trial Site Selections in the European Union 8/26/2008 8:06:43 AM
FDA Approves Eisai Corporation of North America's ALOXI(R) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 8/25/2008 7:10:59 AM
Morphotek Inc. Announces License Agreement for the Development of a Monoclonal Antibody to Treat Prostate Cancer 8/13/2008 8:43:16 AM
Eisai Corporation of North America Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures; FDA's Not Approvable Letter Outlines Pathway to Potential Approval 7/28/2008 6:18:24 AM
12
//-->